In comparison to MMR-proficient/BRAF WT tumors (70.1% CDX2), those with MMR-deficient/BRAFV600E-mutated cancers (29.3% CDX2) have a significantly reduced expression (p < 0.0001). This evidence concerns the gene BRAF and cancer.